# Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

> **NCT00482911** · PHASE2 · TERMINATED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 12 (actual)

## Conditions studied

- Intraocular Melanoma
- Malignant Conjunctival Neoplasm

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** lenalidomide
- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00482911
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Investigator left the institute.
- **Last updated:** 2017-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482911, "Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00482911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*